Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AA

Ratings ESG MSCI

Ratings Sino Biopharmaceutical Limited: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Highlights: Sino Biopharmaceutical Limited
  • The company returns high margins, thereby supporting business profitability.
  • The company has a low valuation given the cash flows generated by its activity.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses: Sino Biopharmaceutical Limited
  • With a 2026 P/E ratio at 20.37 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The group usually releases earnings worse than estimated.

Rating Financials

Sino Biopharmaceutical Limited SectorHong Kong

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Sino Biopharmaceutical Limited SectorHong Kong

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Sino Biopharmaceutical Limited SectorHong Kong

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Sino Biopharmaceutical Limited SectorHong Kong

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Sino Biopharmaceutical Limited SectorHong Kong

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
1.07TCr
AA
1,01000Cr
A
58TCr
BBB
40TCr -
AA
- -
33TCr
AA
28TCr
AAA
28TCr
A
20TCr
A
19TCr
A
16TCr
AA
Average 34.39TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. 1177 Stock
  4. Ratings Sino Biopharmaceutical Limited
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!